Accessed August 5, 2025
RESEARCH USE DISCLAIMER This product is supplied for laboratory and research purposes only
You need both. This article was produced by KFF Health News, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF the independent source for health policy research, polling, and journalism.
Given the high global prevalence of obesity and its strong association with type 2 diabetes and other chronic diseases, Retatrutide emerges as a highly promising research candidate
If eligible, receive a clinically developed and FDA-approved weight loss and prescription medication plan, insurance coordination, and ongoing support
We do not provide dosing, reconstitution, or administration instructions